Afya and Yduqs signed a binding merger agreement on Sept. 23 under which Afya merges into Yduqs at 6.408347 new Yduqs shares per Afya share, leaving Afya holders with 69% of a combined group generating about R$9 billion in revenue.
Back
Afya and Yduqs sign merger creating R$9 billion education group
Afya Limited will merge into Yduqs Participações under a binding agreement signed Sept. 23 that hands Afya holders 69% of a combined Brazilian education group with about R$9 billion in revenue, at an exchange ratio of 6.408347 new Yduqs shares for each Afya share.
"The locked box removes the usual renegotiation lever, so the spread now trades almost entirely on CADE and the two shareholder meetings," said Tomás Ribeiro, a merger-arbitrage strategist at a São Paulo brokerage, who asked not to be named discussing live positions.
The ratio was fixed by reference to the two companies' financial position on June 30, 2026, the locked box date, and will not adjust for changes in EBITDA, results or either stock's trading price. Yduqs survives as the holding company; Afya ceases to exist as a separate legal entity and its Class A shares come off Nasdaq, leaving the combined group listed only on B3 under the Novo Mercado segment. Bertelsmann, through Erste WV Gütersloh GmbH, ends up with 47.4% of the combined company.
The deal carries a two-tier break-up fee. Before both general meetings approve the transaction, R$325 million may become payable if either side breaches obligations covering the convening and holding of its shareholder meeting, the exclusivity undertaking, or if a competing transaction is approved or consummated. After approval, that figure rises to R$650 million if either company fails to satisfy closing conditions for which it is responsible or, once all conditions are met or waived, fails to consummate. No fee is due if shareholders simply reject the deal, provided neither side breached its obligations and no rival bid was approved, and none is payable if Brazil's antitrust authority rejects the transaction or a material adverse effect occurs.
A 17% share of Brazil's medical-school market
The concentration question is the one CADE will weigh. JPMorgan puts the combined company's share of Brazil's medical-school market at 17%, according to Dealroom.co, which reported the deal's roughly R$9 billion revenue scale. Afya is one of Brazil's largest medical education groups by number of medical school seats; Yduqs is one of the country's largest higher education groups overall. Medicine is the segment that matters most economically, carrying the steepest tuition and the most durable demand in Brazilian private higher education.
Closing conditions also include antitrust approval in Brazil, certain third-party consents, the absence of a material adverse effect and other customary terms. The transaction must be consummated no later than March 31, 2028, subject to extension provisions in the merger agreement.
Governance is settled in advance. The combined company's board will have up to 13 members, with Bertelsmann appointing a majority and each of Nicolau Esteves, Advent and Chaim Zaher appointing one, alongside independent directors required by Novo Mercado rules. Bertelsmann, Esteves, Advent and Zaher signed a voting agreement on the same date committing their shares to the transaction at each company's meeting, with several, non-joint break-up fees if they fail to vote as agreed. A shareholders' agreement to be signed at closing carries a 180-day lock-up on all or part of the shares those holders receive.
Afya shareholders who are not qualified institutional buyers, institutional accredited investors or otherwise eligible will not receive stock. Because the merger consideration has not been registered under the U.S. Securities Act, those holders are expected to receive net cash proceeds from a post-closing sale process instead — a mechanical overhang that will be sized once the eligibility certifications are collected.
Afya's advisers were Bank of America Merrill Lynch Banco Múltiplo as financial adviser, Demarest Advogados as Brazilian counsel, Caminati Bueno Advogados as Brazilian antitrust counsel, Maples and Calder (Cayman) as Cayman Islands counsel and Davis Polk & Wardwell as U.S. counsel. Yduqs' advisers were not disclosed in the announcement.
The economics also run through the locked box. Afya expects to distribute adjusted free cash flow generated between the locked box date and closing, and the agreement includes a top-up mechanism in Afya's favor if Yduqs distributions exceed the net cash it generates in the relevant period. Both companies must operate in the ordinary course and observe restrictions on extraordinary actions until closing.
For holders, the trade is now a timing trade. The spread between the two stocks will compress or widen on CADE's review calendar and the scheduling of the two shareholder meetings, not on quarterly results — the ratio is insulated from earnings by design. The next hard checkpoints are the CADE filing and the convening of the Afya and Yduqs general meetings, with March 31, 2028 as the outer boundary if the deal slips.
This article is for informational purposes only and does not constitute investment advice.
Feature
Guides
© 2026 Finture Development Limited (EdWealth). All rights reserved.